Delving into the Latest Updates on Helmholtz-Zentrum Dresden-Rossendorf e. V. with Synapse

Overview

Tags

Neoplasms

Nervous System Diseases

Urogenital Diseases

Diagnostic radiopharmaceuticals

Small molecule drug

Radiolabeled antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	4
Nervous System Diseases	1

Top 5 Drug Type	Count

Diagnostic radiopharmaceuticals	4
Small molecule drug	3
Radiolabeled antibody	1

Top 5 Target	Count

CB2(Cannabinoid CB2 receptor)	3
MCT1 x MCT4	1
IDH1 R132H	1
PSCA(Prostate stem cell antigen)	1
σ1 receptor(Sigma opioid receptor)	1

The two curative treatment modalities for patients with HNSCC - primary chemoradiation (CRT) or primary surgery (often combined with postoperative (C)RT) - are both associated with serious side effects for which reason further stratification, optimization and personalization of treatment is urgently needed. As novel quantitative image analyses are a promising tool for further risk stratification, the investigators training a three-dimensional Convolutional Neural Network on 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging and clinical / histopathological data of a multicentric, retrospective cohort of 1200 patients treated with primary CRT and 800 patients treated with primary surgery at Charité and cooperation institutes in order to predict individual treatment-specific outcomes and identify patients with excellent outcome after primary CRT or primary surgery or unfavorable outcome for both. The trained algorithm of the artificial intelligence will be validated in a prospective trial to see if predicted loco-regional control and recommended treatment strategies are reliable. In total 250 curative HNSCC patients, treated with CRT or primary surgery, will be enrolled on this prospective validation trial with observational character, while biomarker, clinical and FDG-PET data are collected from these patients and follow-up visits will be concluded.

Start Date01 Dec 2021

Sponsor / Collaborator

Charité - Universitätsmedizin Berlin

[+2]

100 Clinical Results associated with Helmholtz-Zentrum Dresden-Rossendorf e. V.

Login to view more data

0 Patents (Medical) associated with Helmholtz-Zentrum Dresden-Rossendorf e. V.

Login to view more data

5,524

Literatures (Medical) associated with Helmholtz-Zentrum Dresden-Rossendorf e. V.

01 Oct 2024·Radiotherapy and Oncology

Transcriptomic and epigenetic landscape of nimorazole-enhanced radiochemotherapy in head and neck cancer

Article

Author: Besso, María José ; Baumann, Michael ; Conde-Lopez, Cristina ; Wijaya Hadiwikarta, Wahyu ; Kurth, Ina ; Bitto, Verena ; Schneider, Karolin ; Bonrouhi, Mahnaz ; Euler-Lange, Rosemarie ; Linge, Annett ; Krause, Mechthild ; Koi, Lydia

BACKGROUNDHypoxia remains a challenge for the therapeutic management of head and neck squamous cell carcinoma (HNSCC). The combination of radiotherapy with nimorazole has shown treatment benefit in HNSCC, but the precise underlying molecular mechanisms remain unclear.PURPOSETo assess and to characterize the transcriptomic/epigenetic landscape of HNSCC tumor models showing differential therapeutic response to fractionated radiochemotherapy (RCTx) combined with nimorazole.MATERIALS/METHODSBulk RNA-sequencing and DNA methylation experiments were conducted using untreated and treated HNSCC xenografts after 10 fractions of RCTx with and without nimorazole. These tumor models (FaDu, SAS, Cal33, SAT and UT-SCC-45) previously showed a heterogeneous response to RCTx with nimorazole. The prognostic impact of candidate genes was assessed using clinical and gene expression data from HNSCC patients treated with primary RCTx within the DKTK-ROG.RESULTSNimorazole responder and non-responder tumor models showed no differences in hypoxia gene signatures However, non-responder models showed upregulation of metabolic pathways. From that, a subset of 15 differentially expressed genes stratified HNSCC patients into low and high-risk groups with distinct outcome.CONCLUSIONIn the present study, we found that nimorazole non-responder models were characterized by upregulation of genes involved in Retinol metabolism and xenobiotic metabolic process pathways, which might contribute to identify mechanisms of resistance to nitroimidazole compounds and potentially expand the repertoire of therapeutic options to treat HNSCC.

01 Sep 2024·Journal of Gastrointestinal Surgery

Bacterial shift and resistance pattern in pancreatic head resections after selective decontamination of the digestive tract – a propensity score-matched analysis

Article

Author: Teske, Christian ; Merboth, Felix ; Distler, Marius ; Weitz, Jürgen ; Radulova-Mauersberger, Olga ; Hempel, Sebastian ; Mibelli, Nicolas ; Selbmann, Anne-Christin ; Oehme, Florian

BACKGROUNDPancreatic head resection is associated with postoperative morbidity, primarily because of infectious complications. The microbiota in these infections is crucial, and selective decontamination of the digestive tract (SDD) aims to mitigate this risk by targeting pathogenic organisms while preserving beneficial flora. This study aimed to determine the effect of SDD on bacterial shifts and resistance patterns in pancreatic head resection.METHODSAll patients who underwent pancreatic head resection either between January 2012 and August 2018 (non-SDD group) or between January 2019 and December 2021 (SDD group) were included. Propensity score-matched analysis was performed to compare the bacterial presence and resistance patterns in bile duct smear tests and postoperative complications.RESULTSPositive bile duct smear tests were observed more often in the non-SDD group (63.5%) than in the SDD group (51.0%). Moreover, the SDD group exhibited a significant reduction in the median number of bacterial species in the bile ducts compared with the non-SDD group (P = .04). However, a notable increase in gram-negative species was observed in the SDD group. The SDD group experienced higher rates of postoperative complications, including relevant pancreatic fistulas (24.8% in the SDD group vs 11.6% in the non-SDD group; P < .01) and delayed gastric emptying (33.8% in the SDD group vs 21.9% in the non-SDD group; P < .01). No significant difference in antibiotic resistance patterns was observed.CONCLUSIONSDD in pancreatic head resection reduces bacterial load in the biliary tract, but it is associated with a shift toward more gram-negative species and higher rates of severe postoperative complications. Our findings suggest that SDD may negatively affect postoperative outcomes and should be carefully considered in clinical practice.

15 Aug 2024·Optics Letters

Terahertz magneto-optical sampling in quartz glass

Article

Author: Ilyakov, Igor ; Kovalev, Sergey ; Wang, Zhe ; Zhu, Changqing ; Ghalgaoui, Ahmed ; Salikhov, Ruslan ; Lindner, Jürgen ; Reinold, Anneke ; Pilch, Patrick

In this Letter, we demonstrate terahertz (THz) magnetic field detection in fused silica with sensitivity that can be easily controlled by sample tilting (for both amplitude and polarization). The proposed technique remains in the linear regime at magnetic fields exceeding 0.3 T (0.9 MV/cm of equivalent electric field) and allows the use of low-cost amorphous materials. Furthermore, the demonstrated effects should be present in a wide variety of materials used as substrates in different THz-pump laser–probe experiments and need to be considered in order to disentangle different contributions to the measured signals.

100 Deals associated with Helmholtz-Zentrum Dresden-Rossendorf e. V.

Login to view more data

100 Translational Medicine associated with Helmholtz-Zentrum Dresden-Rossendorf e. V.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 15 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

2

5

Preclinical

Other

1

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

[18F]AG-120 ( IDH1 R132H )	Glioma More	Preclinical
[18F] RM-365 ( CB2 )	-	Preclinical
18F-FACH (Helmholtz-Zentrum Dresden-Rossendorf) ( MCT1 x MCT4 )	Neoplasms More	Preclinical
[(18)F]5a(Helmholtz-Zentrum Dresden-Rossendorf e. V.) ( σ1 receptor )	Neoplasms More	Preclinical
[177Lu]Lu-CHX-A″-DTPA-7F5 ( PSCA )	Prostatic Cancer More	Preclinical